Irene Ghobrial

Director, Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute

Appears in 1 story

Born: Egypt

Education: Cairo University, Wayne State University

Last updated Nov 2, 2026

Stories

Teclistamab shows deep remissions in high-risk smoldering myeloma trial

New Capabilities

As of September 2026: Co-investigator on the ImmunoPRISM trial

Doctors at Dana-Farber Cancer Institute gave teclistamab, a bispecific antibody already approved for advanced myeloma, to 45 patients with high-risk smoldering multiple myeloma. Complete remission followed in 77.8% of them.

Updated Sep 14